commercial discussions , page-43

Yes - cheaper is a valid point in favour of M+G based on everything we are being told

I also wasn't suggesting that 8mins was good enough and not worth improving on - just posting the facts about where they were at in March and wondering aloud. A several minute improvement may well be worth striving for.

On ds's point and the info he shared about his conference etc discussions, and which is in part a response to Dolce as well, I can imagine that Phillips, as the device manufacturer and provider of the Magnotech technolgy, might be keen to just get on with production, sales and cash flow, and might not be so keen to further improve the assay side if it held things up at all or required a degree of re-engineering by them. But if BioMerieux, as the assay part of the team, were contemplating M+G for broader uses then they may be keener to spend the time to persue it for this product, ...

For Dolce, I guess the less patient amongst us are trying to get better sense of just how quickly M+G might be adopted; the Phillips/BioMerieux POC possible application is likely a decent sized and leading edge one, pretty much ready to go (early?) 2013.So worth a bit of digging around to see what we can see.

just thinking aloud